BeiGene Is Keeping The Faith In IO/IO Combinations

Part 2 of 2

Global head of R&D Lai Wang talked to Scrip about his expectations for a PD-1/TIGIT combination and remaining confident about the potential of IO/IO combinations in cancer despite disappointments. 

two combos
• Source: Shutterstock

BeiGene, Ltd.'s near-term ambitions to bring a second drug to the US market after its BTK inhibitor Brukinsa (zanubrutinib) are linked to the PD-1 inhibitor tislelizumab, which is partnered with Novartis AG and is currently pending at the US Food and Drug Administration for advanced or metastatic esophageal cancer.

Novartis recently announced its decision not to file tislelizumab as a monotherapy in non-small cell lung cancer, however, citing the regulatory environment and commercial market, but is instead waiting for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Focus On Asia

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By 

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By 

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Public Health And Innovation: Addressing Gaps, Pharma’s Role

 

Expert panel including Ashok Venkitaraman, director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Scrip

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By 

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.